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The inhibition of water and glycerol permeation via human aquaglyceroporin-3 (AQP3) by gold(III) complexes has been 
studied by stopped-flow spectroscopy and, for the first time, its mechanism has been described using molecular dynamics 
(MD), combined to density functional theory (DFT) and electrochemical studies. The obtained MD results showed that the 
most effective gold-based inhibitor, anchored to Cys40 in AQP3, is able to induce shrinkage of the pore preventing glycerol 
and water permeation. Moreover, good correlation between the Au(III) complex affinity to Cys binding and AQP3 
inhibition effects was highlighted, while no influence of the different oxidative character of the complexes could be 
observed. 
 
Introduction 
 
Water cellular movement is a prerequisite for all life forms. In fact, 
the fundamental discovery and characterization of an abundant 
protein of the erythrocyte membrane, termed Aquaporin-1 (AQP1), 
25 years ago, represented a paradigm shift in the understanding of 
molecular, membrane and organism water transport. Since then, 
several studies have shown that AQP1 is a member of a widespread 
family of water and solute-permeable membrane proteins – 
Aquaporins (AQPs) - which have been demonstrated to be 
ubiquitous in all domains of life.1 
 
In mammals, the 13 aquaporin isoforms identified so far (AQP0-
12) expressed in a wide range of tissues, organized as tetramers in 
membranes, and can permeate water (orthodox aquaporins), 
glycerol (aquaglyceroporins), and other small solutes.2 These 
membrane channels play important roles in physiology and 
pathophysiology, e.g. maintaining cellular homeostasis and being 
essential in cellular metabolism. Thus, they have been suggested as 
potential targets for drug development.3-5 Specifically, 
aquaglyceroporins regulate glycerol content in epidermis, fat and 
other tissues and appear to be involved in skin hydration, cell 
proliferation, carcinogenesis and fat metabolism.1,6 
 
To validate the various roles of AQPs in health and disease, 
 
 
and to develop AQP-targeted therapies, in addition to genetic 
approaches, the use of selective inhibitors holds great promise. 
However, so far no reported small-molecule AQP inhibitors possess 
sufficient isoform selectivity to be good candidates for clinical 
development.7 In this context, for the first time we reported on the 
potent and selective inhibition of human aquaglyceroporin-3 
(AQP3) by a water-soluble Au(III) compound, [Au(phen)Cl2]Cl (phen 
= 1,10-phenanthroline) (Auphen, Fig. 1).8 Of note, Auphen inhibited 
glycerol transport in human red blood cells (hRBC) with an IC50 = 
0.8 ± 0.08 µM, while having no inhibitory effect on AQP1-mediated 
water permeability. Using in silico approaches, we investigated the 
non-covalent binding of Auphen at a molecular level and found that 
its isoform selectivity is due to the accessibility of Cys40, whose 
thiol group is a likely candidate for direct binding to Au(III) 
complexes.8 The involvement of this residue in the inhibition 
mechanism was further confirmed by site-directed mutagenesis 
studies.9 
 
Figure 1. Gold(III) complexes tested as human AQP3 inhibitors. 
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Additional studies on other Au(III) compounds with different N^N 
ligand scaffolds allowed us to establish preliminary structure-
activity relationships.10 Notably, Quantum Mechanics/Molecular 
Mechanics (QM/MM) calculations showed that the ligand moiety 
may play a major role in orienting the selectivity towards a certain 
isoform,10 stabilizing the position of the inhibitor in the 
extracellular binding pocket 
  
 
 
  
 
and possibly blocking the solutes’ fluǆes. IŶterestiŶglǇ, MoleĐular 
Dynamics (MD) simulations on the adducts of Hg2+ ions (benchmark 
inhibitors of all AQPs11, 12) with AQP3 have allowed us to discover 
that pore closure may be due to protein conformational changes 
upon metal binding, other than direct steric blockage of the channel 
by the inhibitor.13 
 
Following these promising results, we report here on the human 
AQP3 inhibition properties of four Au(III) complexes (Fig. 1), 
including three coordination complexes with a dipyridin-2-ylamine 
(DipyAm) ligand [Au(Dipyam)Cl2]PF6 (1),
14 with 
(pyridyl)benzimidazole type ligands – [Au(PbIm)Cl2] (3) (PbIm = 2-
(pyridin-2-yl)-benzimidazole)15 and [Au(PbImMe)Cl2]PF6 (4) 
(PbImMe = 1-methyl-2-(pyridin-2-yl)-benzimidazole), respectively. 
Moreover, for the first time, an organometallic Au(III) compound 
with a C^N cyclometalated 2-benzylpyridine (pyb-H) ligand (2)16 
was tested as AQP inhibitor. 
 
The mechanism of AQP3 inhibition by the most potent 
compound of the series was studied by MD simulations, allowing to 
disclose important structural changes leading to pore closure upon 
gold binding. Furthermore, the identification of structure-activity 
relationships that may link the electrochemical and 
electronic/structural properties of Au(III) compounds to their 
biological effects, was also explored. Thus, electrochemical methods 
were applied to define the compounds’ eleĐtroŶ-transfer abilities, 
while density functional theory (DFT) calculations were performed 
to further substantiate and interpret the experimental biological 
effects. 
 
subsequently washing the cells with either the thiol containing 
reducing agent b-mercaptoethanol (BME, 1 mM)18 or with the 
sulfur donor L-Cys. In both cases, as shown in Figure S1B, both 
treatments with the competitor molecules led to an almost 
complete recovery of glycerol permeability, ruling out possible 
oxidative modification of amino acid residues by the Au(III) 
complex. 
 
The mechanism of human AQP3 inhibition by complex 4 was 
analysed using classical molecular dynamics (MD). The quaternary 
structure of AQP3 was prepared via homology modelling, following 
an approach previously described by us13 and described in the 
supplementary material. The compound was first parameterised 
using DFT and QM/MM to generate Au(III) parameters for the 
applied forcefield, and then directly bound to the thiolate of Cys40, 
in the form [Au(PbImMe)Cl]2+. Geometry optimisation was 
performed on this fragment (Fig. S2), which was subsequently 
embedded into monomer A of AQP3. The charge of Au was set to 
+3 (Au(III)). Afterwards, five independent MD simulations (0.5 ns) 
were conducted to determine the effect of 4 on water and glycerol 
permeation using either: i) AQP3 or ii) gold-bound AQP3 (AQP3-Au). 
Figure 2 shows the pore size comparison of the structures for 
monomer A obtained from two representative simulations. 
Complex 4 binding to Cys40 induces shrinkage of the pore, impeding 
both glycerol and H2O permeability. 
 
 
Results and discussion 
 
Compounds 1-3 were synthesized adapting previously reported 
procedures (see Experimental section). The new Au(III) complex 4 
was obtained in 82% yield by reaction between 1-methyl-2-(pyridin-
2-yl)-benzimidazole17 in MeCN with an equimolar aqueous solution 
of NaAuCl4 and an excess of PF6 at room temperature (r.t.) for 3 h, 
and characterized by various methods. The gold complexes were 
tested for their AQP1 and AQP3 inhibition properties in hRBC by 
stopped-flow spectroscopy. The obtained results are summarized in 
Table S1 and Figure S1A in the Supplementary material. As 
previously observed for Auphen and related compounds,8, 10 some 
of the new complexes act as inhibitors of glycerol permeation via 
AQP3, but do not affect water permeation via AQP1. The 
coordination complex 1 shows moderate inhibition of water and 
glycerol permeability (IC50 > ϮϬ μMͿ, ǁhiĐh ŵaǇ ďe due to its poor 
stability in physiological environment.14 The organometallic 
compound [Au(pyb-H)Cl2] 2 was also scarcely active up to 50 µM, 
maybe since the metal-carbon bond renders the Au(III) centre less 
prone to ligand exchange reactions. Interestingly, while the neutral 
complex 3 poorly inhibits glycerol transport (IC50 > ϱϬ μMͿ, the 
novel cationic compound [Au(PbImMe)Cl2]PF6 4 is a very potent 
AQP3 inhibitor (IC50 = Ϭ.ϲ ± Ϭ.ϭ μMͿ, eǀeŶ ŵore effective than 
Auphen, and ca. 3 orders of magnitude more potent than 3. The 
reversibility of AQP3 inhibition was also studied pre-treating hRBC 
with the compounds for 30 min at r.t. and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A) Human AQP3 monomer A and (B) AQP3 with modified Cys40 (AQP3-4), 
showing the effect on pore size (based on VDW radii): red = smaller than single H2O, 
green = single H2O, blue = larger than single H2O. Complex 4 and Cys40 are shown in 
ball and stick representation, with atoms coloured by atom type. Generated with 
HOLE20 and VMD21. 
 
From one simulation, 30 snapshots were taken and the pore size of 
each monomer measured as detailed in the supplementary material 
(Fig. S5). Afterwards, in order to validate the observed trend, five 
snapshots were taken (100, 300, 450, 600 and 800 frames) from 
each of the five independent simulations, and the pore size was 
measured in each. The average of size fluctuations was obtained 
(Fig. S6), and allowed to rule out spontaneous pore geometry 
fluctuations during the simulation. Remarkably, from the average of 
the pore size analysis, complex 4 binding to monomer A also 
constricts monomer D, although not sufficiently to hinder the solute 
permeability, but not B and C (Fig. S6). 
 
 
 
 
  
 
The overall protein conformation is conserved upon gold 
binding, as shown by the root mean square displacement (RMSD) 
plots reported in Fig. S3. However, local conformational changes of 
both the protein surface (Fig. S7) and the pore lining can be 
observed. Specifically, binding of the complex induced 
rearrangement of the side chains of the aromatic/arginine 
selectivity filter (ar/R SF) (Fig. 3). Compound 4 does not appear to 
be positioned in the channel in a way that could prevent glycerol or 
water to flow through. However, binding of the complex, just above 
Arg218, prevents this residue from forming a H-bond with the 
backbone, present in the native AQP3, pushing the side-chain into 
the channel area (Fig. 3). These effects suggest that inhibition of 
AQP3’s ǁater aŶd glǇĐerol perŵeaďilitǇ is ŵaiŶlǇ due to proteiŶ 
conformational changes induced by binding of the gold complex to 
Cys40, rather than by the compound’s steriĐ hiŶdraŶĐe, iŶ liŶe ǁith 
the previous MD results on the binding of Hg2+ to AQP3.13 It is 
worth mentioning that similar effects were observed when a longer 
MD simulation was run (8 ns, Fig. S8). 
 
 
Moreover, the observed structural changes upon gold binding 
increase the hydrophobicity of the pore entrance of monomer A, 
due to increased exposure of hydrophobic side chains (Fig. S7). 
Overall, the symmetry of the tetramer is disrupted in the AQP3-Au 
model, as can be seen in Fig. S7, due to increased exposure of 
hydrophilic residues (e.g. Arg50 and Asp125). These relatively small 
changes appear to affect the approaching of glycerol molecules to 
the channels. 
 
To further investigate why the two complexes 3 and 4 have 
different AQP3 inhibitory effects, and assuming Cys40 as the gold 
binding site as in the case of Auphen,9 DFT calculations were 
performed on the adducts between a cysteinato ligand and 
compounds 2-4, as well as Auphen, obtained by 
 
substituting one of the two chlorido ligands (see Fig. S9). The energy 
values of adduct formation are reported in Table S2 and show that a 
larger formation energy is observed for positively charged Au(III) 
complexes with respect to neutral ones. These results support the 
hypothesis that the cationic compounds, [Au(phen)Cl2]
+ and 
[Au(PbImMe)Cl2]
+ 4 can be more easily complexed by cysteinato 
residues than the neutral complexes [Au(pyb)Cl2] 2 and 
[Au(PbIm)Cl2] 3. Therefore, the corresponding AQP3 inhibition 
effects perfectly match this trend. 
 
Finally, we used cyclic voltammetry (CV) to evaluate the 
electrochemical features of the selected Au(III) complexes. Previous 
reports have investigated the electrochemistry of square planar 
Au(III) complexes with chlorido,22 N^N donor 23, 24 and C^N^C 
donor 25, 26 ligands. Typical responses involve the reduction of 
Au(III) to Au(I) at potentials which are heavily influenced by the 
coordinating ligand field strength. Initially, we examined the 
electrochemical response of HAuCl4 in DMSO containing 0.1 M 
TBAP as a supporting electrolyte by CV (Fig. S10, in the 
Supplementary material). As expected, the introduction of strongly 
coordinating ligands, as in Auphen, shifts reduction potentials 
(AuIII/I reduction process) to more positive values.27 Table S3 shows 
values of redox potentials 
 
attributed to reductive (Ered) and oxidative (Eox) electrochemical 
processes. Comparison of CVs of Auphen and 
 
HAuCl4 clearly shows this effect (Figure S11). Substitution of two 
chlorido ligands by a phen scaffold results in a shift of +0.33 V for 
the Au;IIIͿ→Au;IͿ proĐess ;Peak I ǀs. Peak IʹͿ. Siŵilar ǀoltaŵŵetriĐ 
responses to Auphen were obtained for the complexes 2-4 (see 
Table S3) (see Fig. S12-14 in the Supp. material). As expected, 2 has 
the lowest reduction potential due to the C^N coordinating ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. (A) Tetrameric view of human AQP3 bound to complex 4. B) Structure of the ar/R SF of AQP3 (blue) and upon binding of the gold complex (pink). The gold complex 4 is 
shown in black with thin sticks, gold in yellow-gold color and chloride in green, both in ball and stick representation. H-bonds are shown in orange dashed lines (HB), while H-arene 
interactions are shown in green dashed lines. Figures in panel B were generated with MOE.28 
 
Moreover, potentials are shifted to more negative values with 
increasing electron donating character. For example, the PbIm 
ligand is more electron-donating than phen, so potentials are 
shifted by about -0.3 V.29 Furthermore, the complexes yielded a 
seĐoŶd reduĐtioŶ peak ;Peak IIͿ iŶdiĐatiǀe of Au;IͿ→Au;ϬͿ reduĐtioŶ 
process. Interestingly, all peak II potentials are centred at ca. -1.26 
V, made exception for 2 (Table S3). Similar responses were reported 
for a range of Au(III) monodentate 
 
pyridine complexes.30 Interestingly, the organometallic complex 2 is 
predicted to form a C-Au-Cl complex after reduction. In fact, the 
voltammetric response of 2 differs from those of general formula 
Au(N^N)Cl2, with two successive reduction peaks at -0.99 V and -
1.72 V. The main conclusion out of the CV studies is that the 
electrochemical properties of the Au(III) compounds do not directly 
correlate to their AQP3 inhibition effects, as, for example, 
complexes 3 and 4 have 
 
 
 
  
 
similar redox potentials but markedly different effects on glycerol 
permeability. 
 
Conclusions 
 
Due to the broad range of functions of AQPs in physiology and in 
disease states, the necessity of selective modulators (inhibitors) of 
AQPs is impellent, as these could be used as either chemical probes 
to detect their function in biological systems, or as innovative 
therapeutic agents in a variety of disease states. Here, a new series 
of Au(III) complexes has been studied for their AQP3 inhibition 
properties, and the cationic complex 4 was identified as the most 
potent inhibitor of glycerol permeation. Interestingly, the neutral 
complex 3, with a similar ligand system, was scarcely active. DFT 
studies showed that a good correlation can be found between the 
compound’s ĐalĐulated affiŶitǇ for ĐǇsteiŶe residues aŶd their AQPϯ 
inhibitory activity. Instead, electrochemistry results suggest that the 
redox properties of the compounds do not influence their inhibition 
potency, therefore excluding AQP3 inhibition by oxidative damage. 
 
 
Remarkably, MD studies conducted for the first time on the 
Au(III) complex binding to AQPs, have allowed to discover that 
protein conformational changes, upon metal binding to Cys40 in 
human AQP3, are mostly responsible for the observed inhibition of 
water and glycerol permeation. This finding has important 
implications for future inhibitors’ desigŶ, iŶ that other amino acid 
residues (even outside the channel) could be targeted, if their 
modification leads to the necessary conformational changes to 
achieve channel closure. Of note, the Au(III) complexes herewith 
described possess cytotoxic anticancer properties in vitro, and in 
recent years several gold compounds have shown promising 
anticancer effects related to the inhibition of different protein 
targets.31 In this context, we cannot exclude that inhibition of AQP3 
might also contribute to the biological effects of the reported 
compounds towards cancer cells, although other studies are on-
going in our labs to validate this hypothesis. 
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